Pathology and Laboratory Medicine - Global Oncology Academy

Episodes 1-16 of 32

Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
1.25 credits 10 episodes
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
Maximizing Adherence and Persistence via Patient Engagement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits

Prev
1
2
Next

1/2